Weight loss syringes from brands “Wegovy”, “Ozempic” and “Mounjaro” are for sale in Der Achat Apotheke in Mitte, Germany.
Picture Alliance | Picture Alliance | Getty Images
Danish drugmakers are short of Novo NordiskThe U.S. Food and Drug Administration website showed on Friday that it has addressed the popular weight loss and diabetes medications, Wegovi and Ozes.
The resolution may potentially limit how telemedicine plans offer cheaper versions called compound drugs, and two months after health regulators say they are underprivileged YililaiWeight loss and diabetes medication.
Due to the strict amount of treatments from Novo and Eli Lilly, the need for a compounded drug – the need for customized drugs made by combining, mixing or changing the ingredients of the drug thrives.
U.S. regulations allow compound pharmacies to replicate branded drugs that are short of supply but do not allow them to “regularly or excessively”.
Both Novo and Lilly invested billions to strengthen their treatments, which lagged much of the last year.
All doses of Ozempic and Wegovy for Novo diabetes treatment are listed on the FDA website, but the official shortage list has not been removed.
Health regulators usually evaluate whether all back orders have been filled before deciding whether to resolve the shortage.
Several companies, e.g. He and hers and WeiverWatchers provide the active ingredients in complex Semaglutide, Ozempic and Wegovy.
Hims and her stock fell 19% in listing trading.
